Back to Feed
ClinicalTrials.gov|Clinical Trial
Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Chulalongkorn University
Abstract
A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. Phase: EARLY_PHASE1 Status: NOT_YET_RECRUITING Conditions: Relapsed/Refractory Multiple Myeloma (MM) Interventions: Chimeric Antigen Receptor T Cells (CAR-T)
Keywords
Relapsed/Refractory Multiple Myeloma (MM)